Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review

被引：7

作者：

Tsigkas, Grigorios ^{[1
]}

Vakka, Angeliki ^{[1
]}

Apostolos, Anastasios ^{[1
,2
]}

Bousoula, Eleni ^{[3
]}

Vythoulkas-Biotis, Nikolaos ^{[1
]}

Koufou, Eleni-Evangelia ^{[1
]}

Vasilagkos, Georgios ^{[1
]}

Tsiafoutis, Ioannis ^{[4
]}

Hamilos, Michalis ^{[5
]}

Aminian, Adel ^{[6
]}

Davlouros, Periklis ^{[1
]}

机构：

[1] Univ Hosp Patras, Dept Cardiol, Patras 26504, Greece

[2] Natl & Kapodistrian Univ Athens, Hippocrat Gen Hosp, Dept Cardiol 1, Athens 15772, Greece

[3] Tzaneio Gen Hosp, Dept Cardiol, Piraeus 18536, Greece

[4] Red Cross Hosp, Dept Cardiol 1, Athens 11526, Greece

[5] Heraklion Univ Hosp, Dept Cardiol, Iraklion 71500, Crete, Greece

[6] Ctr Hospitalier Univ Charleroi, Dept Cardiol, B-6042 Charleroi, Belgium

来源：

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE | 2023年 / 10卷 / 04期

关键词：

cancer; acute coronary syndrome (ACS); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); triple antithrombotic therapy (TAT); atrial fibrillation (AF); cardiotoxicity; PERCUTANEOUS CORONARY INTERVENTION; PATENT FORAMEN OVALE; ANTITHROMBOTIC THERAPY; ANTICOAGULANT TREATMENT; ATRIAL-FIBRILLATION; OUTCOMES; DISEASE; CLOSURE; STROKE; BREAST;

D O I：

10.3390/jcdd10040135

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

引用

页数：16

共 50 条

[1] Balancing Ischemic and Bleeding Risks of Prolonged Dual Antiplatelet Therapy
Levine, Glenn N.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02): : 194 - 195
[2] INDIVIDUALIZING DURATION OF DUAL ANTIPLATELET THERAPY BASED ON BLEEDING RISK, ISCHEMIC RISK, OR BOTH: AN ANALYSIS FROM THE DUAL ANTIPLATELET THERAPY (DAPT) STUDY
Mihatov, Nino
Secemsky, Eric
Kereiakes, Dean
Steg, Philippe Gabriel
Cutlip, Donald
Kirtane, Ajay
Mehran, Roxana
Zhao, Bokai
Song, Yang
Gibson, C. Michael
Yeh, Robert
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 952 - 952
[3] Balancing ischaemia and bleeding with dual antiplatelet therapy: a resolute endeavour
Stone, Gregg W.
EUROPEAN HEART JOURNAL, 2014, 35 (29) : 1914 - 1916
[4] Dual Antiplatelet Therapy and the Risk of Bleeding Reply
Hansen, Morten Lock
Gislason, Gunnar
Torp-Pedersen, Christian
ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (08) : 787 - 788
[5] Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The Art of Balancing Ischemic Benefits and Bleeding Risks
Bagur, Rodrigo
Jolly, Sanjit S.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (10)
[6] Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Wang, Anxin
Meng, Xia
Tian, Xue
Johnston, S. Claiborne
Li, Hao
Bath, Philip M.
Zuo, Yingting
Xie, Xuewei
Jing, Jing
Lin, Jinxi
Wang, Yilong
Zhao, Xingquan
Li, Zixiao
Jiang, Yong
Liu, Liping
Wang, Feng
Li, Ying
Liu, Jingyao
Wang, Yongjun
ANNALS OF NEUROLOGY, 2022, 91 (03) : 380 - 388
[7] Ischemic and bleeding risk after an acute coronary syndrome in patients with prior history of cancer treated with dual antiplatelet therapy
Munoz Pousa, I.
Raposeiras Roubin, S.
Abu-Assi, E.
Manzano Fernandez, S.
D'Ascenzo, F.
Henriques, P. J. Simao
Saucedo, J.
Ariza Sole, A.
Cambronero Sanchez, F.
Flores Blanco, P. J.
Cespon Fernandez, M.
Caneiro Queija, B.
Cobas Paz, R.
Iniguez Romo, A.
EUROPEAN HEART JOURNAL, 2019, 40 : 280 - 280
[8] Bleeding and dual antiplatelet therapy
Laghrib, Yassine
Salu, Koen
Den Hollander, Philip
Moorkens, Greta
Eeckhout, Bert
ACTA CLINICA BELGICA, 2017, 72 : 41 - 41
[9] Balancing The Risk Between Myocardial Infarction and Clinically Significant Bleeding With Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation
Baber, Usman
Giustino, Gennaro
Sartori, Samantha
Mehran, Roxana
Kini, Annapoorna
Sharma, Samin K.
Dangas, George
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B84 - B84
[10] Dual antiplatelet therapy and bleeding risk after carotid endarterectomy
Whiting, D.
Kotze, C. W.
Lee, J.
Clarke, J.
Senaratne, J.
BRITISH JOURNAL OF SURGERY, 2015, 102 : 18 - 19

← 1 2 3 4 5 →